The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A

Inclusion Criteria: * 18 years or older * without any history of allergy to soy or excessive consumption of soy products * without chronic diseases including renal, liver, heart, respiratory, cardiovascular, malignancies, auto immune disorders, cushing's syndrome, thyroid dysfunction, hepatitis, cirrhosis, biliary disorders, diabetes, gastrointestinal tract diseases affecting the gut absorption and psychiatric disorders considering as an obstacle for patients to prepare written informed consent; * hepatic steatosis grade 2 and higher with fibroscan confirmation (CAP \> 260 dB/m); * without history of excessive alcohol drink (≥10 g/day); * without history of drug consumption with approved positive effects on NAFLD treatment (i.e. metformin, vitamin E, ursodeoxycholic acid, phenytoin, tamoxifen, lithium, corticosteroids and methotrexate) in last three months; * without the history of bariatric surgery or following weight loss diets within 6 months; * without history of smoking; * not being a pregnant or lactating woman Exclusion Criteria: * consuming less than 90% of intended supplements. * unwillingness for study collaboration